Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort.
Saved in:
| Title: | Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort. |
|---|---|
| Authors: | Saeed A; Department of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, USA. saeeda3@upmc.edu.; UPMC Hillman Cancer Center, Pittsburgh, PA, USA. saeeda3@upmc.edu., Park R; Division of Hematology and Medical Oncology, Moffitt Cancer Cente, Tampa, FL, USA., Pathak H; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA., Al-Bzour AN; Department of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, USA., Dai J; Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA., Phadnis M; Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA., Al-Rajabi R; Department of Medicine, Division of Medical Oncology, University of Kansas Medical Center, Kansas City, Ks, USA.; University of Kansas Cancer Center, Kansas City, KS, USA., Kasi A; Department of Medicine, Division of Medical Oncology, University of Kansas Medical Center, Kansas City, Ks, USA.; University of Kansas Cancer Center, Kansas City, KS, USA., Baranda J; Department of Medicine, Division of Medical Oncology, University of Kansas Medical Center, Kansas City, Ks, USA.; University of Kansas Cancer Center, Kansas City, KS, USA., Sun W; Department of Medicine, Division of Medical Oncology, University of Kansas Medical Center, Kansas City, Ks, USA.; University of Kansas Cancer Center, Kansas City, KS, USA., Williamson S; Department of Medicine, Division of Medical Oncology, University of Kansas Medical Center, Kansas City, Ks, USA.; University of Kansas Cancer Center, Kansas City, KS, USA., Chiu YC; UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Osmanbeyoglu HU; UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Madan R; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA., Abushukair H; Department of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, USA., Mulvaney K; University of Kansas Cancer Center, Kansas City, KS, USA., Godwin AK; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA.; University of Kansas Cancer Center, Kansas City, KS, USA.; Kansas Institute for Precision Medicine, University of Kansas Medical Center, Kansas City, KS, USA., Saeed A; Department of Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington, VT, USA. |
| Source: | Nature communications [Nat Commun] 2024 Feb 20; Vol. 15 (1), pp. 1533. Date of Electronic Publication: 2024 Feb 20. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-024-45960-2 |
